Effect of Plasma Rich in Growth Factors on Semen Quality

Vascular Endothelial Growth Factor Overexpression Clinical Trial

Official title:

Effect of Plasma Rich in Growth Factors (PRGF) on Semen Quality

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02708537
• Other study ID #: 1411-BIO-081-MF
• Status: Completed
• Start date: April 2016
• Est. completion date: December 2017

Study information

• Verified date: July 2022
• Source: IVI Bilbao
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The hypothesis is growing semen samples with plasma rich in growth factors (PRGF), because it could improve sperm motility in patients subsidiary TRA, ultimately improving pregnancy rates.

Description:

Platelet growth factors are a group of proteins involved in cellular communication modifying biological responses. Obtaining plasma rich in growth factors is already widespread and simple protocol technique that is being used in various areas of medicine with superb results. Described many of the growth factors present in the PRGF are related to sperm parameters, especially motility The described effects have been studied in mammalian and each growth factor individually. PRGF contains a pool of growth factors and therefore be interesting to analyze their effect on various sperm parameters. One of those parameters is very important for fertilization sperm motility, since the lack of it will prevent displacement by the cervix to meet the egg in the fallopian tube.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: December 2017
• Est. primary completion date: July 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 35 Years

Eligibility

Inclusion Criteria:

• 18-35 years
• more than 5 million sperm per milliliter

Exclusion Criteria:

• Not having genetic and infectious diseases
• Do not suffer mental illness
• Have a family study determined that there is no risk of hereditary diseases
• There have fathered more than 6 children in the country

Related Conditions & MeSH terms

• Vascular Endothelial Growth Factor Overexpression

Intervention

Biological:
• PRGF in candidates for sperm donors
PRGF application on seminal aliquots will be conducted at different concentrations assessing sperm motility.

Locations

Country	Name	City	State
Spain	IVI Bilbao	Leioa	Vizcaya
Spain	IVI Bilbao	Leioa	Vizcaya
Spain	BTI	Vitoria

Sponsors (2)

Lead Sponsor	Collaborator
IVI Bilbao	bTI Vitoria

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluate the percentage of motile sperm adding PRGF versus those samples that growth factors were not added	Within concerted donor visits in IVI Bilbao will be held: Removing Blood 9 mL of blood to obtain plasma rich in factors growth; Seminogram to analyze all semen parameters according to the criteria of the WHO (2010), paying particular attention to sperm motility.; Sperm vitality will be analyzed before and after treatment with PRGF. PRGF application on the seminal aliquots will be conducted at different concentrations assessing sperm motility.	6 months